{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:17:19Z","timestamp":1783070239975,"version":"3.54.6"},"posted":{"date-parts":[[2026,6,30]]},"group-title":"Cardiovascular Medicine","reference-count":34,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"funder":[{"name":"NIH","award":["R01-AR-069572"],"award-info":[{"award-number":["R01-AR-069572"]}]},{"name":"NIH","award":["R01-DK-134625"],"award-info":[{"award-number":["R01-DK-134625"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with Systemic Lupus Erythematosus (SLE), due to both traditional CVD risk factors and SLE specific factors. Although statins are first-line therapy for primary prevention of CVD in the general population, it is unclear whether statins protect against first time cardiovascular events (CVEs) in patients with SLE.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Determine whether statins are protective in primary prevention of CVEs among patients with SLE.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Design, setting, and participants<\/jats:title>\n                  <jats:p>This cohort study is a retrospective analysis of a well-characterized, prospective cohort of patients with SLE with patient follow-up beginning in 2013.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Main outcome and measures<\/jats:title>\n                  <jats:p>CVEs were defined as the occurrence of myocardial infarction, thrombotic stroke, onset of angina, or coronary bypass procedure. Statin use in the prior year was quantified based on standardized defined daily doses (DDD). Rates of occurrence were compared using pooled logistic regression. A multivariable model was performed to adjust for possible confounders.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    The analysis was based on 8708 person-years of follow-up from 1396 cohort participants: 1283 (92%) were women, 567 (41%) Black, and 665 (48%) White. Patients were stratified by use of statin within the last year: none, &lt; standard DDD, or \u2265 standard DDD. The rate of events per 1000 person-years was respectively 5.3, 8.5, and 8.0 (p=0.31) within these 3 groups, suggesting potential lack of protective effect of statin treatment. The rates of CVEs among statin versus non-statin users remained the same after adjusting for and stratifying by total cholesterol level (p=0.18). Significantly higher rates of CVEs occurred among those with BMI 25-30 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    (p=0.0066) and those prescribed \u2265 10 mg\/day of prednisone (p=0.0003). Multivariable analysis also suggested a potential lack of protective effect of statins against CVEs (OR 1.48; 95% CI, 0.79-2.75; p=0.21883) and diabetes mellitus was found to be independently associated with an increased risk for development of CVEs (OR 4.48; 95% CI 1.99-10.08; p=0.00029).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion and Relevance<\/jats:title>\n                  <jats:p>Among patients with SLE, statin use may not be protective in primary prevention of CVEs, regardless of statin exposure. Prednisone use, history of diabetes mellitus, and elevated BMI were drivers of increased cardiovascular risk in univariate analysis. Diabetes mellitus persisted as an independent risk factor for CVEs in a multivariable model. Our work reinforces findings from clinical trials which have shown no reduction in subclinical measures of atherosclerosis with statin use among patients with SLE, as well as a mechanistic substudy which demonstrated that statins are ineffective in normalizing the pro-atherogenic changes induced by SLE.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.06.26.26356369","type":"posted-content","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:56:13Z","timestamp":1782849373000},"source":"Crossref","is-referenced-by-count":0,"title":["Statins May Not be Associated with a Reduction in Primary Cardiovascular Events in Patients with Systemic Lupus Erythematosus"],"prefix":"10.64898","author":[{"given":"Lea R.","family":"Goren","sequence":"first","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6738-4836","authenticated-orcid":false,"given":"Andrea","family":"Fava","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Goldman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Magder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-978X","authenticated-orcid":false,"given":"Luigi","family":"Adamo","sequence":"additional","affiliation":[{"name":"Center for Cardiac Immunology, Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026070301300664000_2026.06.26.26356369v1.1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000346"},{"key":"2026070301300664000_2026.06.26.26356369v1.2","doi-asserted-by":"publisher","DOI":"10.1186\/ar3919"},{"key":"2026070301300664000_2026.06.26.26356369v1.3","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws130"},{"key":"2026070301300664000_2026.06.26.26356369v1.4","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211006790"},{"issue":"6","key":"2026070301300664000_2026.06.26.26356369v1.5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s10067-023-06539-2","article-title":"Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosus","volume":"42","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2026070301300664000_2026.06.26.26356369v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035471"},{"key":"2026070301300664000_2026.06.26.26356369v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev198"},{"key":"2026070301300664000_2026.06.26.26356369v1.8","doi-asserted-by":"publisher","DOI":"10.1191\/096120300678828226"},{"key":"2026070301300664000_2026.06.26.26356369v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.10.002"},{"issue":"2","key":"2026070301300664000_2026.06.26.26356369v1.10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/art.23352","article-title":"Recent corticosteroid use and recent disease activity: Independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?","volume":"59","year":"2008","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2026070301300664000_2026.06.26.26356369v1.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001423"},{"key":"2026070301300664000_2026.06.26.26356369v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"2026070301300664000_2026.06.26.26356369v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.12.1087"},{"key":"2026070301300664000_2026.06.26.26356369v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2014.02.009"},{"key":"2026070301300664000_2026.06.26.26356369v1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-011-0236-1"},{"issue":"1","key":"2026070301300664000_2026.06.26.26356369v1.16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2015.08.030","article-title":"Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study","volume":"243","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026070301300664000_2026.06.26.26356369v1.17","doi-asserted-by":"publisher","DOI":"10.1186\/ar3402"},{"key":"2026070301300664000_2026.06.26.26356369v1.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem186"},{"key":"2026070301300664000_2026.06.26.26356369v1.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.136762"},{"key":"2026070301300664000_2026.06.26.26356369v1.20","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2025-001770"},{"issue":"4","key":"2026070301300664000_2026.06.26.26356369v1.21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.autrev.2015.12.007","article-title":"Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials","volume":"15","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2026070301300664000_2026.06.26.26356369v1.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.24379"},{"issue":"11","key":"2026070301300664000_2026.06.26.26356369v1.23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.14423\/SMJ.0000000000000561","article-title":"Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus","volume":"109","year":"2016","journal-title":"South Med J"},{"key":"2026070301300664000_2026.06.26.26356369v1.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"issue":"6","key":"2026070301300664000_2026.06.26.26356369v1.25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/acr.20440","article-title":"Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial","volume":"63","year":"2011","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2026070301300664000_2026.06.26.26356369v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.01.036"},{"issue":"14","key":"2026070301300664000_2026.06.26.26356369v1.27","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1177\/0961203317722847","article-title":"Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review","volume":"26","year":"2017","journal-title":"Lupus"},{"issue":"9","key":"2026070301300664000_2026.06.26.26356369v1.28","first-page":"514","article-title":"Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy","volume":"55","year":"2019","journal-title":"Medicina (B Aires"},{"issue":"48","key":"2026070301300664000_2026.06.26.26356369v1.29","doi-asserted-by":"crossref","first-page":"e2177","DOI":"10.1097\/MD.0000000000002177","article-title":"Overweight Is a Major Contributor to Atherosclerosis in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease","volume":"94","year":"2015","journal-title":"Medicine"},{"issue":"8","key":"2026070301300664000_2026.06.26.26356369v1.30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/1756-185X.13588","article-title":"Body mass index and glucocorticoid dose contribute to subclinical atherosclerosis in Korean patients with systemic lupus erythematosus: A prospective 4 year follow-up study","volume":"22","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2026070301300664000_2026.06.26.26356369v1.31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001183"},{"key":"2026070301300664000_2026.06.26.26356369v1.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"2026070301300664000_2026.06.26.26356369v1.33","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz022"},{"key":"2026070301300664000_2026.06.26.26356369v1.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021372"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.06.26.26356369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:36:33Z","timestamp":1783067793000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.06.26.26356369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":34,"URL":"https:\/\/doi.org\/10.64898\/2026.06.26.26356369","relation":{},"subject":[],"published":{"date-parts":[[2026,6,30]]},"subtype":"preprint"}}